ECKERT-&-ZIEGLER
14.4.2021 12:01:13 CEST | Business Wire | Press release
Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing.
“We have decided to make this investment to meet the growing global demand for radiopharmaceutical services in both imaging and therapy products. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer," explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. “The new cGMP facility enables positioning as a European production and development partner for specialized pharmaceutical companies and innovative scientists. We offer them a wide range of radiopharmaceutical services under GLP and cGMP conditions."
The new cGMP suite, will enable Eckert & Ziegler to offer complete early development services, including process development and scale-up, CMC manufacturing, product release, stability programs and packaging. The company will be able to manufacture products on a clinical scale for phases I, II and III as well as for commercial use as a radiopharmaceutical contract manufacturer.
Eckert & Ziegler has a global presence as one of the leading partners of the radiopharmaceutical industry and has production and sales sites in 13 countries in Europe, North and South America and Asia.
In Wilmington (MA), USA, a production plant is currently being completed to manufacture Yttrium-90 solution for liver cancer treatment. In the future, the company will expand its European production capacity for Lutetium-177 labeled drugs to its U.S. site. Lutetium-177 is a coveted active ingredient in many new cancer therapy drugs. "Due to the large number of studies in which Lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. Our production sites in Europe, Asia and North America ideally position Eckert & Ziegler to meet this demand," adds Dr. Lutz Helmke.
In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Eckert & Ziegler Medical
The Medical segment of Eckert & Ziegler pools expertise from various areas to provide a comprehensive range of products and services for nuclear medicine, brachytherapy and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Horse Powertrain Reveals Lightweight Hybrid V6 System at Beijing Auto Show 202622.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, has revealed the HORSE W30 – the company’s first production-ready V6 engine – ahead of the Beijing Auto Show 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421176701/en/ The front view of the HORSE W30 engine. The HORSE W30 marks a first for Horse Powertrain, in transferring its expertise in developing optimized three- and four-cylinder engines into the V6 category. By deploying its expertise in this way, Horse Powertrain has developed the lightest V6 on the market and created a hybrid-first V6 with outstanding fuel economy and efficiency. The HORSE W30 is a 3-liter engine that can be fitted in a transverse or longitudinal configuration, allowing it to be packaged in a wide variety of vehicles. The two rows of cylinders are offset at an angle of 90° to lower the engine’s center of gravity, improving ease of installation and optimizi
Montrose Environmental Group Is Now Onterris21.4.2026 22:05:00 CEST | Press release
Earth Day launch of new, unified brand highlights commitment “For Planet & Progress” Montrose Environmental Group (NYSE: MEG, changing to ONT May 4, 2026) will mark Earth Day by rebranding to Onterris. The new, unified brand reflects a purpose and broader role in tackling complex environmental challenges with scientific rigor, operational quality and precise execution. It also aligns expertise and market awareness to position the Company for its next phase of growth. Founded 14 years ago and operating across the U.S., Canada and Australia, the Company is a leading pure-play environmental solutions provider. While the name is new, the mission remains unchanged: advancing our way of life without compromising the integrity of our environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420842892/en/ At the heart of the new brand is a guiding principle: For Planet & Progress. “Onterris is more than a new name. This brand r
SBC Medical Announces Closing of Previously Announced Secondary Public Offering of 3.1 million shares of Common Stock21.4.2026 22:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the closing of its previously announced underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. The proceeds from the offering to the Selling Stockholder were approximately $10.1 million, before deducting underwriting discounts and commissions. The Company did not sell any shares of its common stock in the offering. The Selling Stockholder received all of the proceeds from the offering. Maxim Group LLC acted as the sole book-running manager and Roth Capital Partners acted as the co-manager for the offering. The offering was made pursuant to the Company’s effective shelf registration statement on Form S-3, including a base prospectus, filed with the U.S. Secur
NetApp Wins 2026 Google Cloud Infrastructure Modernization Partner of the Year for Storage21.4.2026 21:00:00 CEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it has received the 2026 Google Cloud Infrastructure Modernization Partner of the Year for Storage Award. NetApp is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers modernize their infrastructure and run enterprise workloads on Google Cloud using Google Cloud NetApp Volumes. “The Google Cloud Partner Awards honor the strategic innovation and measurable value our partners bring to customers,” said Kevin Ichhpurani, President, Global Partner Ecosystem and Channels, Google Cloud. “We are proud to name NetApp a 2026 Google Cloud Partner Award winner, celebrating their role in driving customer success over the last year.” The Google Cloud Infrastructure Modernization Partner of the Year for Storage Award recognizes partners that have helped their customers modernize their infrastructure by leveraging Google Cloud's innovative solutions, resulting in increased
Adtran and GLDS expand partnership to deliver billing-driven, zero-touch automation for subscriber lifecycle management21.4.2026 20:00:00 CEST | Press release
News summary: Service providers need simpler, billing-integrated automation to streamline activation, manage Wi-Fi and cut operational complexity Adtran’s Intellifi® managed Wi-Fi works with GLDS BroadHub®, enabling zero-touch automation from order entry through lifecycle management Solution reduces operational complexity, accelerates time to revenue and preserves operator control within an open ecosystem Adtran today announced a new phase in its long-standing partnership with GLDS, delivering billing-driven, zero-touch automation for subscriber lifecycle management. As broadband and managed Wi-Fi services scale, manual hand-offs between billing, OSS and in-home networking systems are no longer sustainable. By enabling GLDS BroadHub® to orchestrate subscriber creation, service activation and ongoing lifecycle changes across access and the connected home, the solution streamlines operations, accelerates time to revenue and reduces operational complexity. This approach gives broadband pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom